SE8302774D0 - Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten - Google Patents

Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten

Info

Publication number
SE8302774D0
SE8302774D0 SE8302774A SE8302774A SE8302774D0 SE 8302774 D0 SE8302774 D0 SE 8302774D0 SE 8302774 A SE8302774 A SE 8302774A SE 8302774 A SE8302774 A SE 8302774A SE 8302774 D0 SE8302774 D0 SE 8302774D0
Authority
SE
Sweden
Prior art keywords
product
well
refined
preparing
composition containing
Prior art date
Application number
SE8302774A
Other languages
English (en)
Other versions
SE8302774L (sv
SE462017B (sv
Inventor
E E Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of SE8302774D0 publication Critical patent/SE8302774D0/sv
Publication of SE8302774L publication Critical patent/SE8302774L/sv
Publication of SE462017B publication Critical patent/SE462017B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SE8302774A 1982-05-26 1983-05-18 Raffinerat, detoxifierat endotoxin, saett foer dess framstaellning jaemte terapeutisk komposition och dess anvaendning foer framstaellning av laekemedel mot cancer SE462017B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,404 US4436727A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (3)

Publication Number Publication Date
SE8302774D0 true SE8302774D0 (sv) 1983-05-18
SE8302774L SE8302774L (sv) 1983-11-27
SE462017B SE462017B (sv) 1990-04-30

Family

ID=23508804

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8302774A SE462017B (sv) 1982-05-26 1983-05-18 Raffinerat, detoxifierat endotoxin, saett foer dess framstaellning jaemte terapeutisk komposition och dess anvaendning foer framstaellning av laekemedel mot cancer

Country Status (21)

Country Link
US (1) US4436727A (sv)
JP (2) JPS58216121A (sv)
KR (1) KR870000842B1 (sv)
AT (1) AT386337B (sv)
AU (1) AU556532B2 (sv)
BE (1) BE896822A (sv)
CA (1) CA1185899A (sv)
CH (1) CH661526A5 (sv)
DE (1) DE3318569A1 (sv)
DK (1) DK159275C (sv)
FI (1) FI76494C (sv)
FR (1) FR2527613B1 (sv)
GB (1) GB2122204B (sv)
HU (1) HU190491B (sv)
IL (1) IL68713A (sv)
IN (1) IN156144B (sv)
IT (1) IT1164242B (sv)
NL (1) NL194865C (sv)
NO (1) NO154864C (sv)
NZ (1) NZ204298A (sv)
SE (1) SE462017B (sv)

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPS61151157A (ja) * 1984-12-25 1986-07-09 Seiko Instr & Electronics Ltd タンパク質を加水分解する方法
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
JPH01141942U (sv) * 1988-03-24 1989-09-28
JPH01180041U (sv) * 1988-06-09 1989-12-25
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
AU4338189A (en) * 1988-09-23 1990-04-18 University Of Southern California Immunotherapy vaccine for melanoma tumors
JPH02124341U (sv) * 1989-03-24 1990-10-12
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
BR9812079A (pt) 1997-09-10 2000-09-26 Vion Pharmaceuticals Inc Salmonella sp. mutante, lipopolissacarìdeo, processo para inibir o crescimento ou reduzir o volume de um câncer de tumor sólido, composição farmacêutica, e, processo aperfeiçoado para selecionar alterações genéticas em uma bactéria.
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2002513773A (ja) * 1998-05-07 2002-05-14 コリクサ コーポレイション アジュバント組成物及びその使用法
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU769293B2 (en) 1998-12-08 2004-01-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
ATE399793T1 (de) 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DK1265915T3 (da) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
CN1606446A (zh) 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
PT1542732E (pt) 2000-06-20 2009-11-06 Corixa Corp Proteínas de fusão de mycobacterium tuberculosis
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
CA2452382A1 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
PL207168B1 (pl) * 2001-09-20 2010-11-30 Glaxo Group Ltd Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
WO2004005308A2 (en) 2002-07-08 2004-01-15 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
EP2269656B1 (en) 2002-07-15 2014-08-20 Board Of Regents, The University Of Texas Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
ATE494907T1 (de) 2002-07-18 2011-01-15 Univ Washington Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ZA200505302B (en) 2003-01-06 2007-03-28 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
EP2272532B1 (en) 2003-09-02 2016-02-10 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
US8409590B2 (en) * 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
US20090263470A1 (en) 2004-05-28 2009-10-22 Beth-Ann Coller Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
KR20070116650A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
KR20070121814A (ko) 2005-03-31 2007-12-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 클라미디아 감염에 대비한 백신
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
EP3199176B1 (en) * 2007-04-04 2020-02-19 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
BRPI0815008B8 (pt) 2007-08-02 2021-05-25 Biondvax Pharmaceuticals Ltd vacinas multiméricas com múltiplos epítopos contra influenza
WO2009021931A1 (en) 2007-08-13 2009-02-19 Glaxosmithkline Biologicals S.A. Vaccines
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
CA2744739A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EA021393B1 (ru) 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
WO2009095925A2 (en) * 2008-01-31 2009-08-06 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
CN102123724B (zh) 2008-06-19 2018-05-01 变异生技公司 治疗流行性感冒的组合物和方法
BRPI0915960A2 (pt) * 2008-07-18 2019-09-24 Id Biomedical Corp antígenos de polipeptídeos do vírus sincicial respiratório qimérico
CA2738245A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
EP2356225A1 (en) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
NZ700477A (en) 2009-02-17 2016-04-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
JP5796011B2 (ja) 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
EP2477652B1 (en) 2009-09-16 2015-04-15 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2590674B1 (en) 2010-07-06 2017-02-22 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
MX2013004149A (es) 2010-10-15 2013-09-02 Glaxosmithkline Biolog Sa Antigeno gb de citomegalovirus.
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (pt) 2010-11-08 2016-08-02 Infectious Disease Res Inst vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
CN103260642B (zh) 2010-12-14 2018-03-16 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
WO2013038156A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
WO2014042780A1 (en) 2012-08-03 2014-03-20 Infectious Disease Research Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
JP6290918B2 (ja) 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
PT2941258T (pt) 2013-01-02 2019-12-12 Decoy Biosystems Inc Composições e métodos para o tratamento de cancro utilizando bactérias
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
EP3046579A1 (en) 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
CN105992770B (zh) 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
KR102396817B1 (ko) 2014-02-20 2022-05-11 박사르트, 인크. 소장 전달을 위한 제형들
CN106163553B (zh) 2014-04-03 2021-07-23 彼昂德瓦克斯医药有限公司 多聚体-多表位流感多肽的组合物及其产生
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016191553A1 (en) 2015-05-26 2016-12-01 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
EP3791859A1 (en) 2015-06-12 2021-03-17 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN116239693A (zh) 2016-03-14 2023-06-09 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
CA3024313A1 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
US20200282032A1 (en) 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
JP7146732B2 (ja) 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EA201992434A1 (ru) 2017-04-19 2020-03-30 Инститьют Фор Рисерч Ин Байомедисин Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
WO2018219521A1 (en) 2017-05-30 2018-12-06 Glaxosmithkline Biologicals S.A. Methods for manufacturing an adjuvant
EP3638207A1 (en) 2017-06-15 2020-04-22 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
EP3743102A1 (en) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
JP2022542032A (ja) 2019-07-21 2022-09-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療用ウイルスワクチン
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP2022547298A (ja) 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
EP4077356A1 (en) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2021224205A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
EP4158352A1 (en) 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa The perfect fimh by a donor strand
CA3203278A1 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
WO2022136563A2 (en) 2020-12-24 2022-06-30 Plant Bioscience Limited Methods and compositions
KR20230125842A (ko) 2021-01-12 2023-08-29 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
EP4320159A1 (en) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023180677A1 (en) 2022-03-25 2023-09-28 Plant Bioscience Limited Biosynthesis
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE185031C (sv) *
DE472221C (de) * 1924-04-01 1929-02-25 Kalle & Co Akt Ges Verfahren zur Gewinnung der toxischen Komponenten aus den Aufschluessen von Bakterien
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis

Also Published As

Publication number Publication date
JPS6313968B2 (sv) 1988-03-29
FI831749A0 (fi) 1983-05-18
SE8302774L (sv) 1983-11-27
AU1461483A (en) 1983-12-01
DE3318569C2 (sv) 1987-10-29
AT386337B (de) 1988-08-10
GB8313253D0 (en) 1983-06-22
NL194865B (nl) 2003-01-06
SE462017B (sv) 1990-04-30
CH661526A5 (de) 1987-07-31
CA1185899A (en) 1985-04-23
IT1164242B (it) 1987-04-08
FI76494B (fi) 1988-07-29
NO154864B (no) 1986-09-29
FI831749L (fi) 1983-11-27
AU556532B2 (en) 1986-11-06
HU190491B (en) 1986-09-29
FR2527613B1 (fr) 1987-02-27
IT8321287A0 (it) 1983-05-25
DK221883D0 (da) 1983-05-18
GB2122204B (en) 1985-12-24
BE896822A (fr) 1983-09-16
DK221883A (da) 1983-11-27
NZ204298A (en) 1986-10-08
NL194865C (nl) 2003-05-06
DK159275C (da) 1991-02-18
NO154864C (no) 1987-01-07
JPS6345225A (ja) 1988-02-26
GB2122204A (en) 1984-01-11
US4436727A (en) 1984-03-13
FI76494C (sv) 1988-11-10
JPH042573B2 (sv) 1992-01-20
IN156144B (sv) 1985-05-25
FR2527613A1 (fr) 1983-12-02
ATA189483A (de) 1988-01-15
DK159275B (da) 1990-09-24
KR840004510A (ko) 1984-10-22
IL68713A (en) 1986-02-28
IL68713A0 (en) 1983-09-30
NO831855L (no) 1983-11-28
DE3318569A1 (de) 1984-01-12
KR870000842B1 (ko) 1987-04-25
JPS58216121A (ja) 1983-12-15
NL8301842A (nl) 1983-12-16

Similar Documents

Publication Publication Date Title
SE8302774D0 (sv) Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten
GB2122083B (en) Anti-tumour micro-organism obtained products
AU4560479A (en) Composition for prostate therapy
GB2022653A (en) Well treatment with emulsion dispersions
AU1355683A (en) Leather treatment composition
AU507793B2 (en) Disintegrator
DK173883D0 (da) Substituerede 8-phenylxanthiner
AU4200078A (en) Disintegrator
AU501501B2 (en) Tissue stimulation unit
AU5852580A (en) 3,4,5-trihydroxypiperidine compounds
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
AU524639B2 (en) Wood treatment
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
GR3003656T3 (sv)
GB2128612B (en) Improvements in or relating to imaging agents
AU531362B2 (en) Tanning agent
SE7909787L (sv) Sett att framstella en antihemofilifaktor
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
EP0301449A3 (en) Enantiomers of propafenone-containing therapeutic agents
JPS54125894A (en) Treatment chair for doctor
FR2517679B1 (sv)
AU6161180A (en) Schistosomiasis therapy
ATE69551T1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
IL57838A0 (en) N-cyclohexyl-n-methoxyacetamide,its preparation and its use in the preparation of o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamic acid
SU924947A1 (ru) Паромассажная камера

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8302774-8

Format of ref document f/p: F

NUG Patent has lapsed